NCT05924841View on ClinicalTrials.gov

A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

November 10, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Small Cell Lung Cancer
Interventions
DRUG

BL-B01D1

Administration by intravenous infusion

DRUG

SI-B003

Administration by intravenous infusion

Trial Locations (1)

130000

RECRUITING

Jilin Cancer Hospital, Changchun

All Listed Sponsors
lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY